Subscribe to RSS



MannKind Corporation (NASDAQ:MNKD) Reports 4Q Loss On $13 Million Charge – MNKD, CLSN, GILD, ARNA, RNN

Shares of Drug developer MannKind Corporation (NASDAQ:MNKD) dropped on Monday after it posted fourth-quarter loss extended as it acquired a one-time charge associated to the value of a agreement and sustained to study its inhaled diabetes drug Afrezza.

MannKind reported on Monday that it acquired a charge of $13.3Mfollowing adjusting the fair value of agreement. Its research costs surged as it constant new late-stage trials of Afrezza. MannKind has been annoying for years to win authorization of Afrezza and the inhaler that delivers it, and the firm aims to file for marketing authorization in the third quarter of 2013.

Analysts anticipated MannKind to declare a loss of 17 cents a share, according to FactSet.

Moving readers toward the broader market, let’s consider percentage change in stocks prices of other stocks in the similar sector who contribute major role in the market that includes Celsion Corporation (NASDAQ:CLSN) rose +19.38%, Gilead Sciences, Inc. (NASDAQ:GILD) edged down -1.22%, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) which also decreased -1.03% and Rexahn Pharmaceuticals, Inc. (NYSE:RNN) closed up +18.38%.

MannKind Corporation (NASDAQ:MNKD) stock’s trade at beginning with a price of $2.62 and throughout the trading session climbed at a high of $2.65 other than when day-trade ended the stock finally declined -1.92% to $2.56.

The stock is going forward its 52 week low with 63.06% and lagging behind from its 52 week high price with -17.68%. MNKD last month stock price volatility remained 4.38%.

MNKD stock institutional ownership remained 14.79% while insider ownership included 0.77%. In its share capital MNKD has 245.78 million outstanding shares among them 162.15 million shares have been floated in market exchange.

Company’s beta coefficient included 1.05. Beta factors measures the amount of market risk associated with market trade.


Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here

0 comments

Other articlesgo to homepage

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

Shares of BioFuel Energy Corp. (Nasdaq:BIOF) skyrocketed on Thursday’s market activity, currently trading for about $8.20, up $2.14 (or +35.30%), and 5,845,868 of its shares exchanged hands so far BioFuel Energy recently received a preliminary non-binding proposal, which suggested the company acquire acquire all of the equity interests in real-estate developer JBGL Capital and JBGL

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Shares of Zalicus Inc. (Nasdaq:ZLCS) skyrocketed $0.32 (or +31.07%) to $1.35, following the announcement that Epirus Biopharmaceuticals, Inc., which has closed a $36 million Series B financing round, will merge with a wholly-owned subsidiary of Zalicus, to create a global biosimilar enterprise. 13,616,255 shares of Zalicus were traded on Wednesday, increased activity versus its average

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

The trading levels of SmartPros Ltd. (Nasdaq:SPRO) stock exploded on Monday’s market activity, closing at $2.99, up $0.77 (or +34.68%), and 334,315 of its shares exchanged hands during the day, a large increase on activity versus its average volume (3m) of 7,818 On intraday trading, SPRO stock reached a new 52 week high of $3.30

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Shares of JAKKS Pacific, Inc. (Nasdaq:JAKK) soared $0.75 (or +9.96%) to $8.28, and 1,043,882 of its shares exchanged hands on Friday’s trading session. JAKKS Pacific, a leading designer and marketer of toys and consumer products, was upgraded from Market Perform to Outperform and its price target raised from $8.00 to $10.00 by brokerage firm BMO

Crown Equity Holdings Inc Surges on CRWE-PR network Achievement (OTCMKTS:CRWE)

Crown Equity Holdings Inc Surges on CRWE-PR network Achievement (OTCMKTS:CRWE)

With today’s stock market pullback in session, you can take a look at over-the-counter securities (OTC) – Crown Equity Holdings Inc ticker symbol (OTCMKTS:CRWE). Crown Equity Holdings Inc stock price has surged today as high as +13.64% Up 0.0009, currently at +6.06% Up 0.0004, just shy of 300K shares in play in the financial market

read more

Sign Up*

Receive Our Newsletter!

 



 

 

Contacts and information

Social networks

Most popular categories

© 2014 Crown Equity Holdings Inc. All rights reserved.